Today, we are joined by Chris Emerson, who earned his PhD in small-molecule chemistry and completed his postdoctoral research at Stanford University before bringing his scientific rigor to the cannabis industry. He’s now the CEO and Chief Scientist of Level, and was one of the first to introduce cannabis in a precise, pill-based format.

At Level, the team is laser-focused on developing effect-based formulations—using unique cannabinoid combinations and custom ratios designed to deliver real therapeutic value. Chris is especially interested in working with acidic cannabinoids along with lesser-known minor cannabinoids—pushing beyond the usual THC-CBD playbook. Research seems to be increasing in the area of acidic cannabinoids since there is evidence that they provide stronger effects than their converted forms, such as THC and CBD.

In this episode, we dig into his approach to formulation science, what truly differentiates Level from other edibles, how he manages manufacturing and distribution partnerships, and the challenge of maintaining quality and consistency across state lines.

We also talk about what’s next, including plans to expand Level into the hemp market.

https://levelexperience.com

The Innovating Cannabis podcast is produced and hosted by Pam Chmiel, a freelance writer and editor for the Cannabis Industry Journal. 

Get in touch with [email protected].

LinkedIn   Twitter   Instagram

Please like the show to help us reach more listeners🙏🏻

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.